Glucose Lowering Efficacy and Pleiotropic Effects of Sodium-Glucose Cotransporter 2 Inhibitors.
Canagliflozin
Cardiovascular health
Dapagliflozin
Empagliflozin
Ertugliflozin
Gliflozins
Ipragliflozin
Luseogliflozin
Nonalcoholic fatty liver disease
Remogliflozin
Sodium-glucose cotransporter 2 inhibitors
Tofogliflozin
Type 2 diabetes
Journal
Advances in experimental medicine and biology
ISSN: 0065-2598
Titre abrégé: Adv Exp Med Biol
Pays: United States
ID NLM: 0121103
Informations de publication
Date de publication:
2021
2021
Historique:
pubmed:
2
2
2020
medline:
20
1
2021
entrez:
2
2
2020
Statut:
ppublish
Résumé
In type 2 diabetes, the maladaptive upregulation of sodium-glucose cotransporter 2 (SGLT2) protein expression and activity contribute to the maintenance of hyperglycemia. By inhibiting these proteins, SGLT2 inhibitors increase urinary glucose excretion (UGE) that leads to fall in plasma glucose concentrations and improvement in all glycemic parameters. Clinical studies have demonstrated that in patients with type 2 diabetes, SGLT2 inhibitors resulted in sustained reductions in glycated hemoglobin (HbA
Identifiants
pubmed: 32006266
doi: 10.1007/5584_2020_479
doi:
Substances chimiques
Hypoglycemic Agents
0
Sodium-Glucose Transporter 2 Inhibitors
0
Uric Acid
268B43MJ25
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM